GT Biopharma Files 8-K on Security Holder Vote Matters
Ticker: GTBP · Form: 8-K · Filed: Jun 26, 2024 · CIK: 109657
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
GT Biopharma shareholders voted on key company matters, expect updates soon.
AI Summary
GT Biopharma, Inc. filed an 8-K on June 25, 2024, to report on matters submitted to a vote of its security holders. The filing indicates a change in the company's reporting status or a significant corporate event requiring disclosure.
Why It Matters
This filing is important as it signals a significant corporate action or decision made by GT Biopharma's shareholders, which could impact the company's future direction and stock value.
Risk Assessment
Risk Level: medium — Filings related to shareholder votes can indicate significant corporate changes or potential shareholder activism, which may introduce uncertainty.
Key Players & Entities
- GT Biopharma, Inc. (company) — Registrant
- June 25, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 8000 Marina Blvd., Suite 100 (address) — Principal Executive Offices
- Brisbane, CA 94005 (address) — Principal Executive Offices City and Zip
FAQ
What specific matters were submitted for a vote by GT Biopharma's security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 25, 2024.
What is GT Biopharma, Inc.'s state of incorporation?
GT Biopharma, Inc. is incorporated in Delaware.
What is the principal executive office address for GT Biopharma, Inc.?
The principal executive office address is 8000 Marina Blvd., Suite 100, Brisbane, CA 94005.
What is the Commission File Number for GT Biopharma, Inc.?
The Commission File Number for GT Biopharma, Inc. is 1-40023.
Filing Stats: 489 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-06-26 16:17:16
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value GTBP The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 45KB
- 0001493152-24-025269.txt ( ) — 214KB
- gtbp-20240625.xsd (EX-101.SCH) — 3KB
- gtbp-20240625_lab.xml (EX-101.LAB) — 33KB
- gtbp-20240625_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GT BIOPHARMA, INC. Date: June 26, 2024 By: /s/ Alan Urban Alan Urban Chief Financial Officer